Last reviewed · How we verify

Imaging ovarian cancer and malignant lesions — Treatment Landscape & Competitive Intelligence

Imaging ovarian cancer and malignant lesions (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Imaging ovarian cancer and malignant lesions, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cytalux PAFOLACIANINE On Target Labs Optical Imaging Agent Folate receptor alpha 2021-01-01
Cytalux Cytalux Ann & Robert H Lurie Children's Hospital of Chicago Folate receptor alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Ann & Robert H Lurie Children's Hospital of Chicago · 1 drug in Imaging ovarian cancer and malignant lesions
  2. On Target Labs · 1 drug in Imaging ovarian cancer and malignant lesions

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Imaging ovarian cancer and malignant lesions:

Cite this brief

Drug Landscape (2026). Imaging ovarian cancer and malignant lesions — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/imaging-ovarian-cancer-and-malignant-lesions. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing